Anaemia management in patients with chronic kidney disease: Taiwan practice guidelines

Nephrology

Volumn 19, Issue 12, 2014, Pages 735-739

  Hung, Szu Chun ^a   Kuo, Ko Lin ^a   Tarng, Der Cherng ^b,c   Hsu, Chih Cheng ^d   Wu, Mai Szu ^e   Huang, Tung Po ^f  

^a TZU CHI UNIVERSITY   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^e NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^f Wei Gong Memorial General Hospital   (Taiwan)

Author keywords

anaemia; chronic kidney disease; erythropoietin; iron; Taiwan

Indexed keywords

ANTIANEMIC AGENT; FERRITIN; HEMOGLOBIN; IRON; RECOMBINANT ERYTHROPOIETIN; BIOLOGICAL MARKER;

ANEMIA; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; DRUG COST; DRUG MEGADOSE; FERRITIN BLOOD LEVEL; HEART INFARCTION; HEMATOCRIT; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; IRON DEFICIENCY; IRON THERAPY; PERITONEAL DIALYSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; REIMBURSEMENT; RENAL REPLACEMENT THERAPY; REVIEW; SURVIVAL RATE; TAIWAN; BLOOD; DRUG COMBINATION; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; NEPHROLOGY; RENAL INSUFFICIENCY, CHRONIC; STANDARDS; TREATMENT OUTCOME;

ADMINISTRATION, INTRAVENOUS; ANEMIA; BIOLOGICAL MARKERS; DRUG THERAPY, COMBINATION; HEMATINICS; HEMOGLOBINS; HUMANS; IRON; NEPHROLOGY; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; TAIWAN; TREATMENT OUTCOME;

EID: 84936747571     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/nep.12332     Document Type: Review

References (30)

1. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW,. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N. Engl. J. Med. 1987; 316: 73-78.
2. Eschbach JW, Kelly MR, Haley NR, Abels RI, Adamson JW,. Treatment of the anemia of progressive renal failure with recombinant human erythropoietin. N. Engl. J. Med. 1989; 321: 158-163.
3. Eschbach JW, Abdulhadi MH, Browne JK, et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease: Results of a phase III multicenter clinical trial. Ann. Intern. Med. 1989; 111: 992-1000.
4. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N. Engl. J. Med. 1998; 339: 584-590.
5. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N. Engl. J. Med. 2006; 355: 2085-2098.
6. Drueke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N. Engl. J. Med. 2006; 355: 2071-2084.
7. Pfeffer MA, Burdmann EA, Chen CY, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N. Engl. J. Med. 2009; 361: 2019-2032.
8. Freburger JK, Ng LJ, Bradbury BD, Kshirsagar AV, Brookhart MA,. Changing patterns of anemia management in US hemodialysis patients. Am. J. Med. 2012; 125: 906-914.
9. Yang WC, Hwang SJ,. Incidence, prevalence and mortality trends of dialysis end-stage renal disease in Taiwan from 1990 to 2001: The impact of national health insurance. Nephrol. Dial. Transplant. 2008; 23: 3977-3982.
10. Wen CP, Cheng TY, Tsai MK, et al. All-cause mortality attributable to chronic kidney disease: A prospective cohort study based on 462293 adults in Taiwan. Lancet 2008; 371: 2173-2182.
11. United States Renal Data Systems (USRDS) 2012 annual data report.
12. Pisoni RL, Bragg-Gresham JL, Young EW, et al. Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am. J. Kidney Dis. 2004; 44: 94-111.
13. Hasegawa T, Bragg-Gresham JL, Pisoni RL, et al. Changes in anemia management and hemoglobin levels following revision of a bundling policy to incorporate recombinant human erythropoietin. Kidney Int. 2011; 79: 340-346.
14. Fuller DS, Robinson BM, Bieber B, et al. International comparisons illustrate effect of payment and regulatory changes on anemia practice in U.S. hemodialysis patients: The Dialysis Outcomes and Practice Patterns Study. American Society of Nephrology's Kidney Week 2013.
15. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int. Suppl. 2012; 2: S299-310.
16. Tarng DC, Chen TW, Huang TP,. Iron metabolism indices for early prediction of the response and resistance to erythropoietin therapy in maintenance hemodialysis patients. Am. J. Nephrol. 1995; 15: 230-237.
17. Tarng DC, Huang TP, Chen TW,. Mathematical approach for estimating iron needs in hemodialysis patients on erythropoietin therapy. Am. J. Nephrol. 1997; 17: 158-164.
18. Tarng DC, Huang TP,. Hyporesponsiveness to erythropoietin. Perit. Dial. Int. 1997; 17: 99-100.
19. Tarng DC, Huang TP, Chen TW, Yang WC,. Erythropoietin hyporesponsiveness: From iron deficiency to iron overload. Kidney Int. Suppl. 1999; 69: S107-118.
20. Cameron JS,. European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol. Dial. Transplant. 1999; 14 (Suppl 2): 61-65.
21. KDOQI National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am. J. Kidney Dis. 2006; 47: S11-145.
22. Fishbane S, Frei GL, Maesaka J,. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am. J. Kidney Dis. 1995; 26: 41-46.
23. Besarab A, Amin N, Ahsan M, et al. Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients. J. Am. Soc. Nephrol. 2000; 11: 530-538.
24. Rooyakkers TM, Stroes ES, Kooistra MP, et al. Ferric saccharate induces oxygen radical stress and endothelial dysfunction in vivo. Eur. J. Clin. Invest. 2002; 32 (Suppl): 9-16.
25. Drüeke T, Witko-Sarsat V, Massy Z, et al. Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation 2002; 106: 2212-2217.
26. Kuo KL, Hung SC, Lin YP, et al. Intravenous ferric chloride hexahydrate supplementation induced endothelial dysfunction and increased cardiovascular risk among hemodialysis patients. PLoS ONE 2012; 7: e50295.
27. Kalantar-Zadeh K, Regidor DL, McAllister CJ, et al. Time-dependent associations between iron and mortality in hemodialysis patients. J. Am. Soc. Nephrol. 2005; 16: 3070-3080.
28. Tarng DC,. The conundrum of serum ferritin measurement in patients with chronic kidney disease. Nat. Clin. Pract. Nephrol. 2009; 5: 66-67.
29. Hung SC, Lin YP, Tarng DC,. Erythropoiesis-stimulating agents in chronic kidney disease: What have we learned in 25 years? J. Formos. Med. Assoc. 2014; 113: 3-10.
30. Hung SC, Tarng DC,. ESA and iron therapy in chronic kidney disease: A balance between patient safety and hemoglobin target. Kidney Int. 2014; doi: 10.1038/ki.2014.179.